Previous 10 | Next 10 |
Cheap Stocks On Robinhood Moving On Tuesday Whether you call them cheap stocks, penny stocks, or lotto tickets, most day traders hunting for new opportunities typically include stocks under $5 on their list. Why? One of the biggest reasons is regarding how volatile low-priced stocks can be ...
Jasper Therapeutics ( NASDAQ: JSPR ) reported data from the first three people in a phase 1/2 trial evaluating the addition of monoclonal antibody briquilimab to an existing bone marrow transplantation regimen in patients with sickle cell disease (SCD) and beta thalassemia c...
All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within 12-16 days First two participants with peripheral blood chimerism at 60 days after allogeneic stem cell transplant achieved 100% donor myeloid chimerism ...
Jasper Therapeutics press release ( NASDAQ: JSPR ): Q3 GAAP EPS of -$0.32 beats by $0.02 . Cash and cash equivalents as of September 30, 2022 were $51.0 million compared to $84.7 million as of December 31, 2021. The Company expects current cash and cash equivalents to ...
Positive Clinical Data Presented at IEWP Annual Meeting from Investigator Sponsored Study of JSP191 Conditioning Showed 100% Donor Chimerism in First Two Fanconi Anemia Patients Fast Track Designation Granted to JSP191 for Treatment of Patients with Severe Combined Immunodefic...
REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data from the company’s investigator-sponsored study of JSP191 as a conditioning agent i...
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will be participating in the following conferences in September. Cantor F...
Jasper Therapeutics ( NASDAQ: JSPR ) on Thursday said it had got a fast track designation from the U.S. FDA for its monoclonal antibody JSP191 for the treatment of patients with immune disorders undergoing stem cell transplant. Shares of the micro-cap U.S. biotech ju...
JSP191 is currently being evaluated in four ongoing clinical studies in allogeneic hematopoietic stem cell transplant in patients with Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS), SCID, Fanconi anemia and Sickle Cell Disease On track to initiate a new study of...
Jasper Therapeutics press release ( NASDAQ: JSPR ): Q2 GAAP EPS of -$0.29 beats by $0.02 . Cash and cash equivalents as of June 30, 2022 were $60.8 million compared to $84.7 million as of December 31, 2021. The Company expects current cash and cash equivalents to b...
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
Jasper Therapeutics Inc. Website:
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneou...
REDWOOD CITY, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
2024-06-16 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...